Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03387657 · ClinicalTrials.gov registry record · Phase 1

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

A Phase 1 study, sponsored by Sanofi.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT03387657: Completed Phase 1 study, sponsored by Sanofi.

NCT03387657 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03387657, a Phase 1 study, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

Primary Objective: To assess the effects of multiple-dose hydrochlorothiazide (HCTZ) on the steady-state pharmacokinetics (PK) of sotagliflozin. Secondary Objectives: * To assess the safety and tolerability of multiple-dose sotagliflozin with and without co-administration of multiple-dose HCTZ * To assess the effects of multiple-dose sotagliflozin on the steady-state PK of HCTZ * To assess the effects of multiple-dose HCTZ on the steady-state PK of sotagliflozin-3-O-glucuronide

Primary Outcome

Sotagliflozin without HCTZ: AUC to the end of the dosing period (AUCtau)

Interventions

  • DRUG Hydrochlorothiazide
  • DRUG Sotagliflozin (SAR439954)

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-01-03
Est. Completion 2018-03-02
Phase Phase 1
Sanofi

713 total trials

What the finished NCT03387657 record still lists

NCT03387657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide is the first listed.

NCT03387657 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03387657 about?

NCT03387657 is a clinical study titled "A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide". Primary Objective: To assess the effects of multiple-dose hydrochlorothiazide (HCTZ) on the steady-state pharmacokinetics (PK) of sotagliflozin. Secondary Objectives: * To assess the safety and tolerability of multiple-dose sotagliflozin with and without co-administration of multiple-dose HCTZ * ...

What is the current status of trial NCT03387657?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-01-03. Estimated completion is 2018-03-02.

What interventions are being tested in trial NCT03387657?

The interventions under investigation include: Hydrochlorothiazide (DRUG), Sotagliflozin (SAR439954) (DRUG).

Who is sponsoring clinical trial NCT03387657?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03387657's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03387657, the US trial registry maintained by the National Library of Medicine. NCT03387657 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.